Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Allozyne Inc.
Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges
New strategies to overcome safety, solid tumor and other challenges associated with CAR-T therapies – and some early clinical data for patients treated with Poseida's, Celyad's and Autolus' novel products – were featured at the American Association for Cancer Research (AACR) meeting.
Robotic-Assisted Surgery: Taking MIS By Storm
Robotically assisted surgical devices are one of the hottest and fastest growing segments in the market for minimally invasive surgery (MIS) products, with a global market opportunity projected to reach more than $10 billion by 2021. A growing number of competitors hope to capture share and further expand the market by targeting key procedures and geographies with next generation robotic surgery systems and robotic-like technologies designed to improve outcomes and enable more complex procedures to be performed via an MIS approach.
BioNotebook: Merck drops Ariad's ridaforolimus; United Therapeutics, Infinity, Verastem updates; Dipexium, Achaogen IPO terms
Ariad will regain ridaforolimus rights from Merck in November; United Therapeutics considers deals, protects patents; Infinity secures new debt; Verastem buys back VS-4718 rights; and Dipexium, Achaogen set IPO terms.
Deals Shaping The Medical Industry, September 2012
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.